Your session is about to expire
← Back to Search
Cannabinoid
Cannabidiol for Cannabis Use Disorder (LOTUS Trial)
Phase 2
Recruiting
Research Sponsored by University of Colorado, Boulder
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
Summary
"This trial is testing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC) on reducing cannabis use and cannabis use
Who is the study for?
This trial is for adults who regularly use cannabis concentrates (at least 4 times a week) for the past year, have at least moderate Cannabis Use Disorder according to DSM5, and are looking to reduce or stop their cannabis use.
What is being tested?
The study compares hemp-derived CBD with THC (fsCBD), without THC (bsCBD), and placebo in reducing cannabis use and symptoms of CUD. Participants will also receive five weeks of psychotherapy and undergo various assessments over an 8-week period with follow-ups.
What are the potential side effects?
Potential side effects may include changes in appetite, mood alterations, fatigue, gastrointestinal discomfort, and possible interactions with other medications. Effects vary by individual.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Difference in symptoms of cannabis use disorder (CUD)
Difference in withdrawal symptoms
Secondary outcome measures
Difference in alcohol use
Difference in cannabis use
Difference in emotional states
+1 moreOther outcome measures
Moderators of designated outcomes
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: 400mg Full Spectrum Cannabidiol (fsCBD)Experimental Treatment1 Intervention
Group II: 400mg Broad Spectrum Cannabidiol (bsCBD)Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
National Institute on Drug Abuse (NIDA)NIH
2,543 Previous Clinical Trials
3,249,211 Total Patients Enrolled
University of Colorado, BoulderLead Sponsor
122 Previous Clinical Trials
28,994 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger